Personalized prognosis in unresectable hepatocellular carcinoma: Development and validation of a model for transcatheter arterial chemoembolization plus lenvatinib

Figure 1 Validation cohort patient screening flowchart. HCC: Hepatocellular carcinoma; TACE: Transcatheter arterial chemoembolization.

Figure 2 Literature search and screening process for prognostic risk factors associated with receiving transcatheter arterial chemoembolization in combination with lenvatinib for patients with unresectable hepatocellular carcinoma. AFP: Alpha-fetoprotein; ECOG: Eastern Cooperative Oncology Group; HBV: Hepatitis B virus; BCLC: Barcelona Clinic Liver Cancer.

Figure 3 Receiver operating characteristic curves for prediction models in the validation cohort. A: Overall survival; B: Progression-free survival. ROC: Receiver operating characteristic; AUC: Areas under the curve.

Figure 4 Prediction models for in the validation cohort, with 1-year, 2-year, and 3-year calibration curves. A: Overall survival; B: Progression-free survival.

Figure 5 Kaplan-Meier survival curves for prediction models for the three risk groups in the validation group. A: Overall survival; B: Progression-free survival.

Figure 6 Prediction models for in the validation cohort, with 1-year, 2-year, and 3-year decision curves. A: Overall survival; B: Progression-free survival.